Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis

References

• BieloryLAllergic conjunctivitis and the impact of allergic rhinitisCurr Allergy Asthma Rep201010212213420425504
   PubMed Web of Science ®Google Scholar
• HopperJLJenkinsMACarlinJBGilesGGIncrease in the self-reported prevalence of asthma and hay fever in adults over the last generation: a matched parent-offspring studyAust J Public Health19951921201247786934
   PubMedGoogle Scholar
• BlaissMSAllergic rhinoconjunctivitis: burden of diseaseAllergy Asthma Proc200728439339717883905
   PubMed Web of Science ®Google Scholar
• SinghKAxelrodSBieloryLThe epidemiology of ocular and nasal allergy in the United States, 1988–1994J Allergy Clin Immunol20101264778783.e620920769
   PubMed Web of Science ®Google Scholar
• WallaceDVDykewiczMSBernsteinDIThe diagnosis and management of rhinitis: an updated practice parameterJ Allergy Clin Immunol20081222 SupplS1S8418662584
   PubMed Web of Science ®Google Scholar
• TorkildsenGLWilliamsJIGowJAGomesPJAbelsonMBMcNa-maraTRBepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challengeAnn Allergy Asthma Immunol20101051576420642205
   PubMed Web of Science ®Google Scholar
• BieloryBPO’BrienTPBieloryLManagement of seasonal allergic conjunctivitis: guide to therapyActa Ophthalmol201290539940722067457
   PubMed Web of Science ®Google Scholar
• HomMMBieloryLThe anatomical and functional relationship between allergic conjunctivitis and allergic rhinitisAllergy Rhinol (Providence)201343e11011924498515
   PubMedGoogle Scholar
• BieloryLDuttachoudhurySMcMunnABepotastine besilate for the treatment of pruritusExpert Opin Pharmacother201314182553256924191914
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAOral bepotastine: in allergic disordersDrugs201070121579159120687621
   PubMed Web of Science ®Google Scholar
• MacejkoTTBergmannMTWilliamsJIMulticenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitisAm J Ophthalmol20101501122127.e520488431
   PubMed Web of Science ®Google Scholar
• AbelsonMBTorkildsenGLWilliamsJIGowJAGomesPJMcNa-maraTRTime to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase 3, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and childrenClin Ther20093191908192119843481
   PubMed Web of Science ®Google Scholar
• AbelsonMBComparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitisActa Ophthalmol Scand Suppl1999228384210337431
   PubMedGoogle Scholar
• AbelsonMBSpitalnyLCombined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activityAm J Ophthalmol199812567978049645717
   PubMed Web of Science ®Google Scholar
• AbelsonMBTurnerFDAminDPatanol is effective in the treatment of the signs and symptoms of allergic conjunctivitis and allergic rhinoconjunctivitisInvest Ophthalmol Vis Sci200041Suppl4922
   Google Scholar
• D’ArienzoPALeonardiABenschGRandomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge modelClin Ther200224340941611952024
   PubMed Web of Science ®Google Scholar
• AbelsonMBLoefflerOConjunctival allergen challenge: models in the investigation of ocular allergyCurr Allergy Asthma Rep20033436336812791217
   PubMed Web of Science ®Google Scholar
• TorkildsenGNarvekarABergmannMEfficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge modelClin Ophthalmol201591703171326392751
   PubMedGoogle Scholar
• CarrWWNayakASRatnerPHGowJAMcNamaraTRWilliamsJIEfficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trialAllergy Asthma Proc201334324725423484763
   PubMed Web of Science ®Google Scholar
• McCabeCFMcCabeSEComparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preferenceClin Ophthalmol201261731173823152650
   PubMedGoogle Scholar
• BergmannMTWilliamsJIGomesPJTreatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%Clin Ophthalmol201481495150525152611
   PubMedGoogle Scholar
• AbelsonMBChambersWASmithLMConjunctival allergen challenge: a clinical approach to studying allergic conjunctivitisArch Ophthalmol1990108184882297337
   PubMed Web of Science ®Google Scholar
• AbelsonMBGomesPJVogelsonCTEffects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitisCurr Med Res Opin200521568369115969867
   PubMed Web of Science ®Google Scholar
• HorakFBergerUEMenapaceRTothJStübnerPUMarksBDose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis: a double-blind, placebo-controlled studyArzneimittelforschung19984843793849608880
   PubMed Web of Science ®Google Scholar
• HongJBieloryBRosenbergJLBieloryLEfficacy of intranasal corticosteroids for the ocular symptoms of allergic rhinitis: a systematic reviewAllergy Asthma Proc2011321223521262095
   PubMed Web of Science ®Google Scholar
• YanezARodrigoGJIntranasal corticosteroids versus topical H1 receptor antagonists for 476 the treatment of allergic rhinitis: a systematic review with meta-analysisAnn Allergy Asthma Immunol200289547948412452206
   PubMed Web of Science ®Google Scholar
• LightmanSScaddingGKShould intranasal corticosteroids be used for the treatment of ocular symptoms of allergic rhinoconjunctivitis? A review of their efficacy and safety profileInt Arch Allergy Immunol2012158431732522488416
   PubMed Web of Science ®Google Scholar
• BieloryLKatelarisCHLightmanSNaclerioRMTreating the ocular component of allergic rhinoconjunctivitis and related eye disordersMedGenMed20079335
   Google Scholar
• OuslerGWWilcoxKAGuptaGAbelsonMBAn evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochlorideAnn Allergy Asthma Immunol200493546046415562885
   PubMed Web of Science ®Google Scholar
• OuslerGW3rdWorkmanDATorkildsenGLAn open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitisClin Ther200729461161617617284
   PubMed Web of Science ®Google Scholar
• WilliamsJIGowJAKlierSMMcCueSLSalapatekAMMcNamaraTRNon-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilateCurr Med Res Opin201026102329233820735291
   PubMed Web of Science ®Google Scholar
• EllisAKSolimanMSteacyLThe Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapiesAllergy Asthma Clin Immunol20151111625945101
   PubMed Web of Science ®Google Scholar